In kidney injury models, ROS-responsive nanoparticles (RBCM@CeO2/TAK-242) were effective only when combined with anti-inflammatory agents (e.g., TAK-242) that suppress M1 macrophage polarization and TLR4/NF-κB signaling. This evidence concerns the gene NFKB1 and urogenital neoplasm.